1
Introduction 26
Pathological accumulation of extracellular matrix (ECM) accompanies the formation of all 27 solid tumors(1-3). The tumor ECM is composed primarily of interstitial collagen that is 28 progressively reorganized and stiffened (2, 4) . The collagenous fibrotic tumor ECM compromises 29 treatment and is linked to poor patient prognosis (5) (6) (7) (8) . Tumor biopsy analysis showed that a 30 thick fibrous collagenous ECM associates with less differentiated tumors and that this 31 phenotype predicts poor patient survival, emphasizing the relevance of collagen 32 architecture (1, 4, 9) . Patients with pancreatic ductal adenocarcinomas (PDACs) that are 33 surrounded by stiff, thick fibrous collagens have a shorter survival, and invasive breast 34 carcinomas with the stiffest ECM stroma at their invasive front are the most aggressive (1, 2) . 35
These observations suggest that stromal stiffness reflects collagen organization may be an 36 important prognostic variable. Consistently, preclinical studies using organotypic cultures and 37 rodent models provide plausible evidence for a causal relationship between collagen 38 organization, stromal stiffness, tumor cell invasion in culture, and metastasis in vivo (10) (11) (12) (13) (14) . 39
These findings underscore the clinical relevance of collagen architecture and stiffness to 40 malignancy, and emphasize the need to clarify the molecular nature of the collagenous ECM so 41 that new biomarkers can be identified and anti-cancer therapeutics may be 42 developed (1, 2, 15, 16) . 43
Interstitial type I fibrillar collagen is the ECM component that contributes most 44 significantly to the tensile strength of tissue (17) . The tensile strength of interstitial collagen 45 depends upon the activities of two major families of enzymes: the lysyl hydroxylases (LH; gene 46 name procollagen-lysine, 2-oxoglutarate 5-dioxygenase or PLOD) and the lysyl oxidases (LOX), 47 which regulate fibrillogenesis of newly synthesized collagen molecules through intermolecular 48 covalent crosslinking (18) (19) (20) (21) . Fibrotic human tumors express high levels of LOX and LH 49 enzymes(22) . Tumor grade and overall patient survival associate with total tissue LOX and 50 PLOD2 mRNA (21, (23) (24) (25) . Pharmacological or antibody-mediated inhibition of LOX in To clarify the role of collagen crosslinking in tumor fibrosis we developed a crosslinked 77 amino acid analysis (xAAA) method that enabled the characterization and quantification of 78 specific collagen crosslinks in tissues across a wide range of collagen levels. We utilized solid 79 phase extraction (SPE) enrichment followed by high pH amide hydrophilic chromatography 80 (HILIC) coupled to a benchtop orbitrap (QExactive) mass spectrometer for these 81 measurements. The validated method detected all known LOX-generated crosslinks including 82 divalent (lysinonorleucine, dihydroxy lysinonorleucine), trivalent (pyridinoline and deoxy-83 pyridinoline) and tetravalent (desmosine and isodesmosine) crosslinked amino acids linearly 84 over four orders of magnitude, with calculated limits of quantification (LLOQ) in the femtomolar 85 range (Suppl. Fig. 1 between collagen crosslinking and abundance in excised human clinical specimens with very 87 low to very high collagen concentrations and varying mechanical properties (Suppl. Fig 2) . The 88 method also identified a subset of hydroxylysine aldehyde (Hyl ald )-derived collagen crosslinks 89 (HLCCs) crucial for the mechanical strength of tissue (17, 37) . 90
We next obtained snap-frozen biospecimens of normal human breast tissue (N=10; age 91 between 22 and 58) and human tumor biopsies representing early stage (stage 1-2) invasive 92 breast cancers (IBC) excised from mastectomy specimens. Molecular subtyping that subdivides 93 human breast tumors stratified by estrogen receptor (ER+) and human epidermal growth factor 94 receptor two (HER2+) status and ER/PR/HER2-negative (triple negative; TN) is a key 95 determinant used to direct the treatment of breast cancer patients. Accordingly, we chose 96 human breast tumor biopsies that represented ER+ (N=8; age between 42 and 71); HER2+ 97 (N=6; age between 40 and 76) and TN (N=6; age between 50 and 71). H&E stained tissue 98 sections confirmed the presence of normal glandular structures in the normal controls and 99 invasive breast cancer in the tumor specimens ( Fig. 1a; top panels) . Polarized light imaging of 100
Picrosirius-stained (PS) tissue revealed that the normal breast tissue stroma had very little 101 fibrillar collagen, whereas stromal tissue in all patients with IBCs contained abundant fibrillar 102 collagen ( Fig. 1a ; middle panels) that second harmonic generation (SHG) imaging indicated 103 was thicker and more linearized (Fig. 1a; bottom panels) . Polarized light microscopy and two-104 photon imaging further revealed that the level of fibrosis in the tissue was higher in HER2+ as 105 compared to the ER+ breast tumors, and was further increased in the TN tumors, consistent 106 with our previous report that TN tumors contain a high density of aligned collagen fibers ( Fig.  107 1a; middle and bottom panels)(2). AFM microindentation revealed a significant increase in the 108 elastic modulus of the stroma associated with the invasive front of all the IBC tissues ( Fig.  109   1b)(2,4,12) . xAAA analysis revealed a significant increase in total collagen crosslinking in all the 110 IBCs ( Fig. 1c, Suppl. Fig. 5 ). These findings are consistent with an association between 111 collagen crosslinks, tissue fibrosis and stromal stiffness, as has been previously documented in 112 experimental murine models of mammary cancer (12) . Interestingly, when we subdivided the 113 IBC collagen crosslinking analysis into breast tumor subtype the most significant increase in 114 total collagen crosslinks was calculated to be in the TN breast tumors (Fig. 1i) . Furthermore, 115 biochemical quantification of total tissue collagen 1A1 or 1A2 did not account for the higher total 116 number of collagen crosslinks in the TN breast tumor tissue ( Fig. 1k) . Instead, molecular 117 characterization of the isolated tissue collagen revealed that the TN tumors had a distinctive 118 crosslink profile due to a strong preference for a combination of DHLNL, Pyr, and d-Pyr 119 crosslinks ( Fig. 1d-j) . Subtype analysis further revealed that the level of hydroxylysine 120 aldehyde-derived collagen crosslinks (HLCCs) in the TN subtype correlated significantly and 121 positively with the stiffness of the stroma at the invasive front of the tumor tissue ( Fig. 1l) . These 122 findings highlight the importance of HLCC collagen crosslinking in breast cancer aggression. 123
Increased collagen crosslinking correlates with high expression of stromal LOX and 124

PLOD2 in aggressive tumor subtypes 125
To determine if the observed increase in collagen crosslinking and stromal stiffness in 126 TN tumors was related to the expression levels of enzymes implicated in regulating collagen 127 crosslinking, we analyzed publicly available human breast cancer gene expression array data (n 128 = 1904) for the genes coding these enzymes and examined their correlation to breast cancer 129 subtype. Bioinformatics analyses revealed a significant increase in the major collagen 130 crosslinking enzyme LOX, but not lysyl oxidase like two (LOXL2), in the more aggressive HER2 131 and TN tumor subtypes and indicated that LOX levels were particularly high in TN tumors ( Fig.  132 2a-b). The arrays also showed bulk gene expression of PLOD2, the major regulator of HLCC 133 accumulation, to be highly upregulated in aggressive human TN breast cancers ( Fig. 2c) . 134
To gain insight into the cellular sources of LOX and LH2 in human tumors, we used laser 135 capture microdissection to isolate regions of tumor epithelium and stroma to identify the origins 136 of LOX and LH2 in invasive human breast cancers (38, 39) . Gene expression analysis of stromal 137 and epithelial compartments revealed that the stromal cells in the tumor tissue expressed 138 significantly more LOX and PLOD2 than the associated tumor epithelium. The data further 139 indicated that this relationship was more evident in the breast tissue from women with ER-/PR-140 breast cancer that is frequently the more aggressive tumor subclass ( Fig. 2d-g) . 141
The findings implicate, but do not definitively demonstrate a role for LOX and PLOD2 in 142 generating the increased level and greater complexity of collagen crosslinking we quantified in 143 the more aggressive human breast tumors. Nevertheless, the combination of these gene 144 expression data with our findings showing increased collagen crosslink abundance provide 145 compelling evidence to suggest that increased expression of LOX and PLOD2, particularly from 146 stromal cells, likely contribute to elevated levels of collagen crosslinks and HLCCs in TN tumors. 147 Moreover, given that TN tumors are the most aggressive and lethal breast cancer, these data 148 link human breast tumor aggression to increased levels of total and complex collagen crosslinks 149 and higher stromal stiffness. Accordingly, the findings implicate the collagen crosslinking 150 enzymes LOX and LH2, and by extension factors that regulate their expression, in breast 151 cancer aggression. 152
Stromal -and not epithelial -crosslinking enzymes regulate tissue fibrosis and 153 collagen crosslinking in vivo 154
Prior studies demonstrated that both cancer cell lines and stromal fibroblasts express 155 LOX and LH2 to induce tissue stiffening and fibrosis implying they also drove collagen cross-156 linking. Seminal articles identified hypoxia-induced HIF1a as a key regulator of tumor epithelial 157 LOX and LH2 expression and suggested epithelial secretion of these enzymes drives collagen 158 remodeling, crosslinking and stiffening that foster tumor cell dissemination and primes the pre-159 metastatic niche to facilitate metastatic colonization (22, 24, 25) . Our analysis of breast cancer 160 clinical specimens showed that the stromal cells in the breast tissue express higher levels of 161 LOX and PLOD2 as compared to the breast tumor epithelium. Moreover, our prior studies 162 showed LOX is expressed in stromal fibroblasts in a transgenic mouse model of ErbB2-induced 163 mammary tumor malignancy. Furthermore, we demonstrated that fibroblasts expressing LOX 164 injected into a cleared mammary fat pad not only induced ECM remodeling and stiffening but 165 also potentiated the growth and malignant progression of pre-malignant tumor cells injected into 166 the modified glands (12). Thus, the relative contribution of tumor-and stromal-derived collagen 167 crosslinking enzymes to tumor fibrosis, ECM remodeling and collagen crosslinking remains 168 unclear; particularly in the context of spontaneous tumors and patient tumors in which the ECM 169 evolves concurrently with tumor progression. 170
To directly test the extent to which epithelial-derived LOX can crosslink collagen and 171 induce tissue fibrosis and stromal stiffening in mammary tissue, we created a genetically 172 engineered mouse model (GEMM) in which we targeted and controlled luminal epithelial-173 specific expression of mouse LOX using the MMTV-rtTA promoter (Epithelial LOX 174 overexpression [OX]). (Fig. 3a, Suppl. Fig. 6a-b ). We crossed these mice into the PyMT 175 spontaneous mammary tumor model to enhanced LOX expression in the mammary tumor 176 epithelium (PyMT epithelial LOX OX) and assayed their stromal phenotype as compared to the 177 mammary glands from age-matched PyMT control mice (PyMT). Again, despite confirming 178 ectopic LOX expression and elevated levels of cleaved LOX protein in the mammary tumor 179 epithelial compartment (Suppl . Fig 6c) , we were not able to detect any increase in the levels, 180 nor any altered organization of the mammary gland interstitial collagen (Fig 3b-c) . Moreover, 181 xAAA crosslinking analysis revealed that the level of collagen crosslinks between the PyMT 182 control and PyMT epithelial LOX OX mammary gland stroma were indistinguishable ( Fig. 3d-i) . 183
Nevertheless and importantly, we could easily and consistently detect a significant increase in 184 fibrillar collagens, collagen crosslinks and stromal stiffness in the PyMT mammary tumors as 185 compared to age-matched FVB mammary glands lacking tumors ( Fig. 4c,f-k) . These studies 186 both validate the sensitivity of our crosslinking assay and imply that tumor epithelial LOX is not 187 the primary driver of collagen crosslinking and stiffening in endogenous mammary tumors. 188
We and others have implicated stromal fibroblast LOX as a key promoter of epithelial 189 tumor progression and aggression (12, 14, 40) . To directly test the functionality of the ectopically-190 expressed LOX and the relevance of fibroblast-specific expression of LOX, we next created 191 mouse cohorts of PyMT GEMMs in which we restricted ectopic LOX expression to the stromal 192 population using the Col1a1-tTA promoter (MMTV-PyMT+/-; Col1a1-tTA+/-;TetO_mLox+/-; 193 herein denoted PyMT LOX OX) ( Fig. 4a, Suppl. Fig. 7b ). To begin with, induction of LOX in the 194 stromal cells markedly enhanced the amount of fibrillar collagen in the MMTV-PyMT LOX OX 195 mammary glands, as revealed by quantification of polarized images of Picrosirius Red stained 196 tissue ( Fig. 4b , second row images; quantified in c). We also detected more and thicker 197 linearized interstitial collagen when LOX was increased in the stromal cells by two-photon 198 second harmonic generation imaging ( Fig. 4b, third row panels) . In addition, immunostaining 199 revealed more phosphorylated tyrosine 397 focal adhesion kinase protein ( pY397 FAK) in the 200 mammary epithelium of the glands in which stromal LOX was elevated (Fig. 4b, bottom  201 panels), likely reflecting the increase in elasticity that we measured in the tissue stroma using 202 atomic force microscopy (AFM) indentation(12) ( Fig. 4d-e & Suppl. Fig. 9b ). Consistently, we 203 measured higher levels of total collagen crosslinks in the PyMT LOX OX mice as compared to 204 the levels quantified in the MMTV-PyMT control glands ( Fig. 4f) . Furthermore, the most 205 significant increases that we quantified in the PyMT LOX OX glands were dihydroxy 206 lysinonorleucine (DHLNL) and pyridinoline (Pyr) crosslinks ( Fig. 4g-k) , which are the crosslinks 207 generated through the HLCC pathway that promote mechanical stability and strength in skeletal 208 tissue (37, 41) . Of note, we did not detect any increase in DHLNL or Pyr in the mammary glands 209 in which ectopic LOX expression was elevated in the mammary epithelium using the MMTV 210 promoter ( Fig. 3g-h) . These findings imply that stromal cells are the primary regulators of 211 interstitial collagen crosslinking and stromal stiffening in mammary tumors. 212
Tissue inflammation regulates tissue fibrosis, collagen crosslinking and stromal 213
stiffening 214 Cancer progression is accompanied by tissue inflammation and the most aggressive 215 human breast tumors with the stiffest invasive stroma harbor the highest number of 216 macrophages (2, 35) . Consistently, decreasing the number of tumor macrophages, either through 217 genetic ablation of macrophage colony stimulating factor (CSF-1) or via pharmacological and 218 inhibitory antibody treatment with anti-CSF1 antibody, reduces lung metastasis in the PyMT 219 mouse model of mammary cancer (33, 34, 42, 43) . Interestingly, macrophage ablation was more 220 effective at preventing lung metastasis in the PyMT mammary tumor model when the treatment 221 was initiated early, prior to malignant transformation and coincident with the onset of tissue 222 fibrosis(33). These findings raise the intriguing possibility that macrophage ablation may 223 regulate tumor aggression, at least in part, by promoting collagen remodeling and inducing ECM 224 crosslinking and stromal stiffening ( Fig. 3 & 4) . 225
To assess the possibility that there is a causal association between macrophage-226 mediated tissue inflammation, tumor fibrosis and ECM stiffening and mammary tumor 227 aggression, PyMT mice were treated with anti-CSF-1 antibody or a non-specific IgG control 228 antibody commencing at four weeks of age, prior to the onset of ductal hyperplasia(44). Mouse 229 cohorts (6/treatment group/time point) were sacrificed at eight and eleven weeks of age. 230
Immunostaining confirmed efficient reduction of mammary tumor tissue macrophages at eight 231 weeks of age, as evidenced by significantly reduced F4-80 immunostaining that was also 232 evident in the eleven week old treated tissue ( Fig. 5a top panel, Suppl. Fig. 8a ). The excised 233 lungs from the eleven week mice confirmed reduced frequency of lung metastasis in the anti-234 CSF-1 antibody-treated group (Fig. 5b) , consistent with our prior work documenting a significant 235 inhibition of lung metastasis in fourteen week old mice when anti-CSF-1 treatment was initiated 236 at four weeks(33). The mammary glands from the eight and eleven week old mice were excised 237 and analyzed for fibrosis and biomechanical properties (Fig. 5a ,c-i). Despite confirming an 238 equivalent number of fibroblasts in the treated and nontreated groups, polarized images of PS 239 stained tissue revealed lower levels of total fibrillar collagen in the stroma of the eight week anti-240 CSF1 antibody treated group ( Fig. 5a , third row panel, Suppl. Fig. 10b-c) . AFM 241 microindentation additionally demonstrated that the tissue stroma from both the eight week old 242 ( Fig. 5d) , and the eleven week old (not shown) mammary glands was softer, likely accounting 243 for the reduced integrin mechanosignaling detected in the CSF1-antibody treated tissue, as 244 revealed by less intense staining for pY397 FAK (Fig. 5a, second row panel) . Consistently, we 245 also observed reduced levels of Lox mRNA in eight week, anti-CSF1 treated mice by in situ 246 hybridization (Fig. 5a, bottom panel, Fig. 5e ). In agreement with prior studies, nearly all the 247 detected Lox mRNA was restricted to stromal cells (Fig 5a, bottom panel)(14) . These findings 248 suggest that reducing the level of tumor-associated macrophages (TAMs) not only prevents 249 lung metastasis but also concomitantly reduces tissue fibrosis and stiffening, likely by 250 preventing stromal cell activation. 251
TAMs secrete abundant TGFβ that stimulates fibroblast differentiation to a myofibroblast 252 phenotype and induces expression of collagen crosslinking enzymes including LOX(14). PCR 253 analysis of flow activated cell sorted (FACS) cells from the transformed mammary glands of 254
PyMT mice (11 weeks) confirmed that the TAMs expressed by far the highest levels of TGFβ, 255 as compared to neoplastic epithelium and the cancer-associated fibroblasts (Fig. 5j) . These 256 findings suggest that the tumor infiltrating macrophages could promote fibrosis and stromal 257 stiffening through secreted TGFβ; a finding supported by a strong stromal pSMAD2 (SMAD2 258 pS465/467) in the IgG control antibody-treated PyMT mammary glands ( Fig. 5k-l) . To examine 259 whether TAM recruitment could regulate collagen crosslinking in human tumors we queried a 260 publicly available human breast tumor gene expression data set for TAM markers and collagen 261 modifying enzymes. Consistent with a role for TAMs in stimulating expression of collagen 262 modifying enzymes, gene expression of the TAM marker CD163 positively correlated with both 263 LOX and PLOD2 but not LOXL2 in human breast tumors (n = 1904) ( Fig. 5m-o) . Moreover, co-264 staining of resected human breast tumors with the macrophage/monocyte marker CD68 and the 265 downstream TGFβ signaling molecule pSMAD2 Ser465/467 revealed a significant positive 266 correlation between pSMAD2 Ser465/467 and infiltrating tumor macrophages at the invasive 267 front of human breast tumors ( Fig. 5p-q) . Furthermore, FACS analysis established a significant 268 correlation between the infiltrating tumor associated macrophages, as demonstrated by 269 CD14 hi CD11b + HLA-DR + cell surface markers normalized to total CD45 infiltrating cells, and the 270 elastic modulus of the invasive front of human invasive breast cancers (Fig. 5r) . These findings 271 suggest that tumor inflammation and macrophage secreted factors such as TGFβ could 272 promote tissue fibrosis by enhancing fibroblast expression of the collagen crosslinking enzymes 273 LOX and PLOD2, but not LOXL2, to induce collagen crosslinking and stromal stiffening. 274
LH2 inhibition reduces lung metastasis and stromal LH2 predicts poor prognosis in 275 breast cancer patients 276
Using the data set generated from the micro-dissected tumors, we next explored the clinical 277 relevance of epithelial vs. stromal LOX and PLOD2 expression by assessing their relative 278 contribution to overall survival in breast cancer patients. Surprisingly, neither stromal cell nor 279 epithelial LOX predicted overall patient survival in this cohort ( Fig. 6a-b) . However, the findings 280 clearly showed that overexpression of stromal PLOD2, but not epithelial PLOD2, significantly 281 correlated with poor breast cancer patient prognosis ( Fig. 6c-d) . The data provide further 282 evidence that HLCCs, formed primarily through the activities of collagen crosslinking enzymes 283 expressed by stromal cells, promote breast tumor aggression that contributes to poorer overall 284 survival. The findings also highlight the importance of the collagen crosslinking profile and its 285 potential impact on stromal stiffness in tumor aggression. 286 LH2 (the protein encoded by PLOD2) is a key enzyme that regulates the level of HLCC 287 crosslinking of fibrillar collagen and consequently contributes substantially to the tensile 288 properties of the tissue stroma (19, 23, 45) . We quantified the highest level of HLCC crosslinking 289 and the stiffest invasive front in the breast tissue from women with the most aggressive breast 290 cancers ( Fig. 1j) . Consistently, when we analyzed the gene expression data from a published 291 cohort of breast cancer patients we observed that ER-/HER2-(TN; n=133) breast cancers 292 express the highest level of the PLOD2 gene transcript as compared to the levels expressed in 293 HER2+ (n=73) and ER+/HER2-(luminal, n=314) breast tumors (Suppl. Fig. 11a )(46). Further 294 analysis showed that high PLOD2 expression in breast cancer patients with HER2+ and TN 295 tumors significantly predicts reduced distant metastasis-free survival (DMFS), as well as 296 increased risk of relapse in TN tumors (Suppl. Fig. 11b-d)(46,47) . These findings implicate 297 PLOD2/LH2 as a key regulator of breast tumor aggression through its ability to induce the 298 HLCC crosslinking of fibrillar collagens that enhance the stiffness of the tumor stroma. 299
To evaluate whether LH2 does enhance stromal stiffness to promote breast tumor 300 aggression, we systemically treated a cohort of PyMT mice with the LH2 inhibitor minoxidil or 301 vehicle (PBS) from five weeks of age until sacrifice at either 11-12 weeks or 13-14 weeks of age 302 ( Fig. 6e) . Consistent with its predicted role in enhancing stromal stiffness through modifying the 303 nature of collagen crosslinks, AFM microindentation revealed that the phenotypically-similar 304 collagen-rich ECM adjacent to tumors from the minoxidil treated mice (see polarized imaging of 305 picrosirius red stained tissue) was significantly softer when compared to the vehicle-treated 306 age/stage-matched PyMT mice ( Fig. 6f-h) . Furthermore, inhibiting LH2 also significantly 307 decreased lung metastasis, causally linking HLCC collagen crosslinking to stiffness-mediated 308 breast tumor aggression ( Fig. 6i) . Our gene expression data from the epithelial and stromal 309 microdissection cohort indicated that stromal PLOD2, but not epithelial PLOD2, strongly 310 predicted poor survival in breast cancer patients. Therefore, we next sought to definitively 311 assess the relative contribution of stromal versus neoplastic epithelial LH2 protein expression to 312 human breast tumor aggression using a large tissue array of annotated human breast tumor 313 biopsies. To accomplish this, we first developed an LH2 immunostaining protocol (IHC) and 314 then we analyzed neoplastic epithelial and stromal expression of the LH2 enzyme in tissue 315 biopsies from a large cohort of histopathologically classified breast cancer patients (N=505) with 316 accompanying clinical information and follow up data (Suppl. the relationship between epithelial versus stromal expression and breast cancer patient 319 outcome was calculated ( Fig. 6j; Suppl Fig. 12a ). IHC scoring analysis revealed that only a 320 modest number of patients with poorly differentiated breast tumors expressed moderate to high 321 levels of epithelial LH2 (Suppl. Fig. 12b ); a finding that accords with prior links between tumor 322 size, hypoxia and LH2-dependent tumor aggression(23,24). More strikingly however, we 323 observed that a disproportionately high number of breast cancer patients with moderately and 324 poorly differentiated breast tumors had high stromal cell LH2 (indicated by an H score of above 325 230; Fig. 6k ). These data and our observation that even well differentiated breast tumors 326 express intermediate levels of stromal cell LH2 (H score above 120 and equal or less than 230) 327 imply that stromal cell LH2, rather than epithelial LH2, may be a more robust indicator of breast 328 tumor aggression. Consistently, stratification of breast tumor patient analysis into ER+/HER2-329 (N=296); HER2+ (N=36) and TN (N=32) showed an enrichment for intermediate and high 330 stromal LH2 H-score in the more aggressive cancer subtypes (Suppl. Table 3 ). Furthermore, we uncovered a significant correlation between high stromal cell LH2 H-332 score and shorter breast cancer patient-specific survival when adjusted for age at diagnosis 333 ( Fig. 6l) . We also established a significant association between stromal cell but not epithelial 334 LH2 levels and survival in lymph node positive breast cancer patients but not lymph node 335 negative breast cancers ( Fig. 6m-n; Suppl Fig. 12d-e ). These clinical data identify stromal cell 336 LH2 as a novel biomarker with potential to predict metastatic disease and poor patient survival 337 among breast cancers overall, as well as within the highest risk TN breast cancer subtype. 338 339
Discussion: 340
We identified infiltrating macrophages as key regulators of stromal cell-mediated 341 collagen crosslinking, stromal stiffening and tumor metastasis. Our clinical findings corroborated 342 our experimental results, revealing significant associations between macrophages and collagen 343 crosslinking enzymes providing evidence for a critical impact of inflammatory stromal cell-344 mediated collagen crosslinking and stromal stiffening in tumor aggression and patient outcome. 345
Diverse subsets of myeloid cells account for adverse patient outcomes because they 346 differentially promote angiogenesis, tumor cell intravasation, and suppress the anti-tumor 347 immune response(48). Our results expand this perspective to include a key role for early 348 infiltrating macrophages in initiating a collagen crosslinking and stiffening program that 349 ultimately fosters tumor aggression and progression. We also determined that TN breast 350 cancers contain much higher amounts of LH2-and LOX-derived collagen crosslinks. 351
Specifically, we demonstrated that significantly higher levels of HLCC crosslinks could explain 352 their higher stromal stiffness and aggressiveness(2). Intriguingly, in depth collagen analysis 353 suggested that each breast tumor subtype exhibits a distinct collagen organization, stiffness and 354 crosslinking profile, raising the possibility that distinct collagen architectures and crosslinking 355 signatures may reflect differences in tissue pathobiology. Indeed, TN breast cancers often 356 present with high macrophage infiltration; an observation that is consistent with our AFM, two 357 photon and collagen crosslinking analysis data(2). Given that the immune cell infiltrate 358 significantly influences treatment response it is tempting to speculate that distinct collagen 359 architectures, crosslinking signatures and stiffnesses similarly regulate therapeutic efficacy. 360
We determined that stromal LH2 is a robust predictor of survival in breast cancer 361 patients, especially in those that are lymph node positive, supporting a potentially important 362 clinical link to stromal collagen crosslinking. Our data also revealed that both the upregulation of 363 crosslinking enzymes and in turn, collagen crosslinking, occur at an early stage of malignancy 364 that is concurrent with tumor cell invasion and coincident with the accumulation of infiltrating 365 macrophages(49). In part, this may explain why therapeutics targeting LOX and LOXL2 have 366 thus far failed to significantly prolong cancer patient survival. Substantial levels of collagen 367 crosslinking are likely to have occurred prior to therapy administration, and while these agents 368 may prevent further crosslinking activity, they are not capable of reversing crosslinks or collagen 369 modifications already present in the tissue. The early initiation of collagen crosslinking also 370 suggests that a detectable increase in stromal LH2 may provide an early prognostic marker of 371 disease progression and aggression that could inform treatment strategies. To that end, our 372 results show for the first time that LH2-derived collagen crosslinks are not only a distinct feature 373 of enhanced stromal stiffening in TN breast cancer but are able to predict distant metastasis-374 free survival. These results also suggest that the profile of collagen crosslinks, and not simply 375 crosslink abundance alone, may play a role in promoting tumor aggression, thus warranting 376 further investigations into the contributions of HLCCs to ECM mechanical properties and tumor 377 aggression. 378
Our findings identify fibroblasts as the dominant cell population that promotes 379 reorganization and crosslinking of interstitial collagen to stiffen the tissue stroma. Only stromal-380 targeted, and not epithelial-targeted, tissue-specific inducible LOX produced any measurable 381 change in collagen architecture, stiffness or crosslink abundance in a spontaneous tumor 382 (25, 50, 51) . Our conclusion is consistent with earlier work in which we failed to detect any 383 alterations in fibrosis, collagen organization or stiffness when LOXL2 was either genetically-384 ablated, or ectopically-increased in the mammary epithelium of PyMT mouse tumors, despite 385 documenting a significant impact on metastasis(40). Nevertheless, it is possible that our bulk 386 assay would not detect any small increase in collagen crosslinking induced by invading tumor 387 cells expressing high levels of LOX. To this end, immortalized tumor cells engineered to 388 overexpress LOXL2 injected orthotopically as a bolus of cells were able to induce fibrosis and 389 quantifiable changes in collagen remodeling and tissue stiffening; a finding we too confirmed 390 using isolated PyMT tumor cells overexpressing the LOXL2 enzyme(40). Nevertheless, our data 391 support the notion that in spontaneous tumors, the proximity of stromal cells to collagen and 392 their significantly higher expression of crosslinking enzymes dictate the profile and extent of 393 collagen crosslinking. Given that LH2 modifies collagen intracellularly and stromal cells secrete 394 the vast majority of the interstitial fibrillar collagen, it is not surprising that this is the case(52,53). 395
Moreover, our results stress the necessity of choosing an appropriate model to study tumor 396 associated ECM remodeling and suggest that orthotopic models may fail to accurately 397 recapitulate the natural evolution of ECM in tumor progression. 398
Our findings not only underscore the importance of stromal stiffness and collagen 399 crosslinking in cancer-associated fibrosis and disease aggression, but also define in more detail 400 the molecular nature of collagen modifications that accompany pathological fibrosis. Clarifying 401 the nature of collagen modifications and specific mechanisms regulating those alterations in 402 fibrosis will assist in the strategic design of novel, efficacious strategies to combat progressive 403 fibrosis and should prove instrumental in enabling further experimentation to understand 404 pathological fibrosis. Indeed, defining the molecular regulators that stimulate collagen cross-405 linking, and mechanisms that distinguish resolvable from non-resolvable fibrosis would identify 406 attractive therapeutic targets for several pathological fibrotic diseases with limited treatment 407 options. 408
Methods: 409
Human breast specimen acquisition and processing 410
Fresh human breast specimens from breast reduction, prophylaxis, or breast tumor mastectomy 411 were either embedded in an optimum cutting temperature (OCT) aqueous embedding 412 compound (Tissue-Plus, Scigen, Cat# 4583) within a disposable plastic base mold (Fisher, Cat# 413 22-363-554) and were snap frozen by direct immersion into liquid nitrogen and kept at -80°C 414 freezer until cryo-sectioning for analysis, or specimens were formalin fixed and paraffin 415 embedded (FFPE). All human breast specimens were collected from prospective patients 416 undergoing surgical resection at UCSF or Duke University Medical Center between 2010 and 417 2014. The selected specimens were de-identified, stored, and analyzed according to the 418 procedures described in Institutional Review Board (IRB) Protocol #10-03832 and #10-05046, 419 approved by the UCSF Committee of Human Resources and the Duke's IRB (Pro00034242)(2). 420
Mouse studies 421
Macrophages were depleted in MMTV-PyMT mice by i.p. injections of 1mg of anti-CSF1 422 antibody clone 5A1 or an IgG1 control every 7 days starting at 4 weeks of age. Mice were 423 sacrificed at 8 and 11 weeks of age for tissue analysis. 424
Minoxidil and PBS vehicle was administered by i.p. injections of 3 mg/kg minoxidil in PBS three 425 times per week starting at 6 weeks of age. Mice were sacrificed at 11-12 and 13-14 weeks of 426 age for tissue analysis. 427
Generation of mice 428
All mouse studies were maintained under pathogen-free conditions and performed in 429 accordance with the Institutional Animal Care and Use Committee and the Laboratory Animal 
Preparation of human breast specimens for hydrolysis 455
OCT was removed from tissue blocks by first transferring biospecimens to a conical tube and 456 then performing 5X washes with 70% ethanol followed by 5X washes with 18 MΩ H 2O 48 . Each 457 wash consisted of vortexing the sample for 15 minutes at 4°C and then centrifuging at 18,000 x 458 g for 15 minutes at 4°C. Between 1 and 3 milligrams of tissue was washed with 1X PBS buffer 459 by vortexing for 15 minutes at 4°C and then sonicated on ice for 20 seconds using a Sonic 460
Dismembrator M100 (ThermoFisher, San Jose, CA, USA). The homogenate was then 461 centrifuged at 18,000 x g for 20 minutes at 4°C. The supernatant was removed and the pellet 462 was re-suspended in 1mg/mL NaBH4 (prepared in 0.1N NaOH) in 1X PBS for 1 hour at 4°C with 463 vortexing. The reaction was neutralized by adding glacial acetic acid to a final concentration of 464 0.1% (pH ~ 3 -4)(57). The sample was then centrifuged at 18,000 x g for 20 minutes at 4°C. The 465 supernatant was removed and the pellet was washed three times with 18 MΩ H2O to remove 466 residual salt that could interfere with downstream LC-MS/MS analysis. The remaining pellet was 467 dried under vacuum for further analysis. 468
Protein hydrolysis 469
The dried sample was placed in a glass hydrolysis vessel and hydrolyzed in 6N HCl, 0.1% 470 phenol. The hydrolysis vessel is flushed with N2 gas, sealed and placed in a 110°C oven for 24 471 hours. After hydrolysis, the sample was cooled to room temperature and then placed at -80°C 472 for 30 minutes prior to lyophilization. The dried sample was re-hydrated in 100μL of 18 MΩ H2O 473 for 5 minutes, then 100 μL of glacial acetic acid for 5 minutes and finally 400 μL of butan-1-ol for 474 5 minutes. Importantly, 10 μL of sample is removed after re-hydration in water and saved for 475 determination of hydroxyproline content. 476
Preparation of crosslink enrichment column 477
CF-11 cellulose powder is loaded in a slurry of butan-1-ol: glacial acetic acid, water (4:1:1) 478 solution onto a Nanosep MF GHP 0.45μm spin columns until a settled resin bed volume of 479 approximately 5mm is achieved. The resin is washed with 1.5 mL 4:1:1 organic mixture using an 480 in-house vacuum manifold set up. Re-hydrated samples are then loaded onto individual 481 columns, the vacuum is turned on and the sample is pulled through the resin into glass 482 collection vials. The flow through is again passed over the resin to ensure maximal binding of 483 crosslinked amino acids and set aside. The column is then washed with 1.5 mL of fresh 4:1:1 484 organic mixture. A fresh collection vessel is placed under the column and 750 μL of 18 MΩ H2O 485 is used to elute crosslinked amino acids off of the CF-11 resin. The eluent is then placed in a 486 speed vac and run until complete dryness. Dried eluent is then reconstituted in a buffer 487 appropriate for downstream MS analysis on amide HILIC UHPLC columns. 488
UHPLC analysis 489
Up to 20 µL of tissue hydrolysates were analyzed on a Vanquish UPHLC system 490 (ThermoFisher, San Jose, CA, USA) using an Acquity UHPLC BEH Amide column (2.1 x 491 100mm, 1.7 μm particle size -Waters, Milford, MA, USA). Samples were separated using a 5 492 minute gradient elution (55% -40% Mobile phase B) at 250 μL/min (mobile phase: (A) 10mM 493 ammonium acetate adjusted to pH 10.2 with NH4OH (B) 95% acetonitrile, 5% Mobile Phase A, 494 pH 10.2, column temperature: 35°C. 495
MS data acquisition 496
The Vanquish UPHLC system (ThermoFisher, San Jose, CA, USA) was coupled online with a 497
QExactive mass spectrometer (Thermo, San Jose, CA, USA), and operated in two different 498 modes -1. Full MS mode (2 μscans) at 70,000 resolution from 75 to 600 m/z operated in 499 positive ion mode and 2. PRM mode at 17,500 resolution with an inclusion list of in-tact 500 crosslinked amino acid masses ( Supplementary Table 2 ), and an isolation window of 4 m/z. 501
Both modes were operated with 4 kV spray voltage, 15 sheath gas and 5 auxiliary gas. 502
Calibration was performed before each analysis using a positive calibration mix (Piercenet -503 Thermo Fisher, Rockford, IL, USA). Limits of detection (LOD) were characterized by 504 determining the smallest injected crosslinked amino acids (LNL, DHLNL, d-Pyr,) amount 505 required to provide a signal to noise (S/N) ratio greater than three using < 5 ppm error on the 506 accurate intact mass. Based on a conservative definition for Limit of Quantification (LOQ), these 507 values were calculated to be threefold higher than determined LODs. 508
MS data analysis 509
MS Data acquired from the QExactive were converted from a raw file format to .mzXML format 510 using MassMatrix (Cleveland, OH, USA). Assignment of crosslinked amino acids was performed 511 using MAVEN (Princeton, NJ, USA)(58). The MAVEN software platform provides the means to 512 evaluate data acquired in Full MS and PRM modes and the import of in-house curated peak lists 513 for rapid validation of features. Normalization of crosslinked amino acid peak areas was 514 performed using two parameters, 1. Hydroxy proline content and 2. Tissue dry weight pre-515 hydrolysis (in milligrams)(57). Hydroxy proline content is determined by running a 1:10 dilution 516 of the pre-enrichment sample through the Full MS mode (only) described above and exporting 517 peak areas for each run. 518
Quantification of crosslinked amino acids 519
Relative quantification of crosslinked amino acids was performed by exporting peak areas from 520 MAVEN into GraphPad (La Jolla, CA, USA) and normalizing based on the two parameters 521 described above. Statistical analysis, including T test and ANOVA (significance threshold for P 522 values <0.05) were performed on normalized peak areas. Total crosslink plots were generated 523 by summing normalized peak areas for all crosslinks in a given sample. Total HLCC plots were 524 generated by summing normalized peak areas for all HLCC (DHLNL, Pyr, dPyr) crosslinks in a 525 given sample. 526
Picrosirius red staining and quantification 527 FFPE tissue sections were stained using 0.1% Picrosirius red (Direct Red 80, Sigma-Aldrich, 528
Cat# 365548 and picric acid solution, Sigma-Aldrich, Cat# P6744) and counterstained with 529
Weigert's hematoxylin (Cancer Diagnostics, Cat# CM3951), as previously described (2). 530
Polarized light images were acquired using an Olympus IX81 microscope fitted with an analyzer 531 (U-ANT) and a polarizer (U-POT, Olympus) oriented parallel and orthogonal to each other. 532
Images were quantified using an ImageJ macro to determine percentage area coverage per 533 field of view. The ImageJ macro is available at https://github.com/northcottj/picrosirius-red. 534
Second harmonic generation image acquisition 535
Second harmonic generation (SHG) imaging was performed using a custom-built two-photon 536 microscope setup equipped resonant-scanning instruments based on published designs 537 containing a five-PMT array (Hamamatsu, C7950), as previously published(2). The setup was 538 used with two channel simultaneous video rate acquisition via two PMT detectors and an 539 excitation laser (2W MaiTai Ti-Sapphire laser, 710-920 nm excitation range). SHG imaging was 540 performed on a Prairie Technology Ultima System attached to an Olympus BX-51 fixed stage 541 microscope equipped with a 25X (NA 1.05) water immersion objective. Paraformaldehyde-fixed 542 or FFPE tissue sections were exposed to polarized laser light at a wavelength of 830 nm and 543 emitted light was separated using a filter set (short pass filter, 720 nm; dichroic mirror, 495 nm; 544 band pass filter, 475/40 nm). Images of x-y planes at a resolution of 0.656 mm per pixel were 545
captured using at open-source Micro-Magellan software suite. 546
Immunofluorescence/Immunohistochemistry 547
Immunofluorescence staining was performed as previously described (2). Briefly, mouse tissues 548 were harvested and fixed with 10% buffered formalin phosphate (Fisher, Cat# 100-20) for 16-24 549 hours at room temperature and then further processed and paraffin-embedded. Five-µm 550 sections dried for 30 minutes in 60 º C, follow by deparaffinization and rehydration. Antigen 551 retrieval was perform using DAKO Target Retrieval Solution (DAKO, Cat# S1699) for five 552 minutes in a pressure cooker set to high pressure. Tissue sections were incubated with anti-553 Quantification of stromal nuclear SMAD2 pS465/467 was performed using Imaris 9. Surfaces 569 were created around each nucleus and epithelial nuclei were manually excluded based on 570 cytokeratin signal and cell morphology. The means of the mean nuclear signal intensity for all 571 stromal nuclei were calculated for each field of view and averaged for every animal. 572
Lungs from 11 week old IgG1 control and anti-CSF1 treated PyMT mice were cut into 5 micron 573 sections from 5 layers with 100 microns between the first three layers and 50 microns between 574 the last two layers. Sections were analyzed for metastases by PyMT staining. Antigen retrieval 575 was performed in Tris-EDTA buffer at pH 9 for four minutes in a pressure cooker set to low 576 pressure. Tissue sections were incubated with anti-PyMT antibody (Novus Biologicals, Cat# NB-577 100-2749, dilution 1:250) overnight at 4°C and with a biotinylated anti-rat antibody for 1 hour at 578 room temperature. Vectastain Elite ABC (Vector, Cat# PK6100) and ImmPACT DAB Peroxidase 579 (Vector, Cat# SK-4105) were used for signal detection and nuclei were counterstained with 580 methyl green. 581 mRNA In Situ Hybridization 582 Fresh, RNase-free FFPE sections were stained with RNAscope multiplex fluorescent reagent kit 583 V2 according to standard manufacturer protocol. Target retrieval was performed using 8 minute 584 incubation in a pressure cooker set to low pressure. Opal 520 and Opal 570 (PerkinElmer) were 585 used at 1:1500 for target visualization. 586
Gene expression by RT-qPCR 587
Total RNA was reverse-transcribed using random primers (Amersham Bioscienes) and results were normalized to 18S RNA to control for varying cDNA concentration between samples. The primer sequences used are 18s forward 5'-GGATGCGTGCATTTATCAGA-3' and reverse 5'-GGCGACTACCATCGAAAGTT-3', Lox forward 5'-CGGGAGACCGTACTGGAAGT-3' and reverse 5'-CCCAGCCACATAGATCGCAT-3', Loxl2 forward 5'-CACAGGCACTACCACAGCAT-3' and reverse 5'-CCAAAGTTGGCACACTCGTA-3', and Tgfb1 forward 5'-TCATGTCATGGATGGTGCCC-3' and reverse 5'-GTCACTGGAGTTGTACGGCA-3'.
Atomic force microscopy data acquisition 588
Atomic force microscopy (AFM) measurements were performed as previously described (2). 589
Briefly, 20µm OCT-embedded frozen human breast tissue or 30µm mouse mammary gland 590 sections were fast thawed by immersion in PBS at room temperature. Next, these sections were 591 immersed in PBS containing phosphatase inhibitors (Roche, Cat# 04906845001), protease 592 inhibitor (Roche, Cat# 04693124001), and propidium iodide (ACROS, Cat# 440300250) and 593 placed on the stage for AFM measurements. AFM indentations were performed using an 594 MFP3D-BIO inverted optical AFM (Asylum Research) mounted on a Nikon TE2000-U inverted 595 fluorescent microscope. Silicon nitride cantilevers were used with a spring constant of 0.06 N m -596 1 and a borosilicate glass spherical tip with 5 µm diameter (Novascan Tech). The cantilever was 597 calibrated using the thermal oscillation method prior to each experiment. The indentation rate 598 was held constant within each study but varied between 2-20 μms -1 with a maximum force of 2 599 nN between studies. Force maps were obtained as a raster series of indentations utilizing the 600 FMAP function of the IGOR PRO build supplied by Asylum Research. Elastic properties of ECM 601 were reckoned using the Hertz model. A Poisson's ratio of 0.5 was used in the calculation of the 602 Young's elastic modulus. 603
Western blotting 604
Snap frozen tissues were ground while frozen and lysed in 2% SDS containing protease and 605 phosphatase inhibitor. Samples were boiled for 5 minutes (95°C) and loaded onto the SDS-606 polyacrylamide gel, and protein was separated at 110 constant volts. 607
The protein was transferred onto a pre-wet polyvinylidene difluoride (PVDF) membrane (100% 608 methanol, 1 minute) at 250 mA for 2 hours. The PVDF membrane was rinsed with TBST and 609 non-specific binding was blocked with 5% nonfat dry milk dissolved in TBST. The membrane 610 was then incubated with the primary antibody overnight at 4°C, washed with TBST, incubated 611 with horseradish-peroxidase conjugated secondary antibody (1 hour, room temperature; dilution 612 1:5000), washed with TBST, and detected with the chemiluminescence system Quantum HRP 613 substrate (Advansta #K-12042). Quantification was performed using gel densitometry in 614
ImageJ. Primary antibodies used are anti-LOX (1:1000, Abcam Cat# ab174316) and anti-E-615 cadherin (1:1000, Cell Signlaing Cat#3195). 616 
Tumor evaluation 694
Tumor samples from incident breast cancer cases in MDCS were collected, and a tissue 695 microarray (TMA) including two 1-mm cores from each tumor was constructed (Beecher, WI, 696 USA). Within the study population (N=910), tumor tissue cores were accessible from 718 697 patients. Four-μm sections dried for one hour in 60 º C were automatically pretreated using the 698 Autostainer plus, DAKO staining equipment with Dako kit K8010 (Dako, DK). A primary mouse 699 monoclonal Lysyl Hydroxylase 2 (LH2) antibody (Origene; Cat# TA803224, dilution 1:150) was 700 used for the immunohistochemical staining. 701 TMA cores were analyzed by a cohort of 4 anatomic pathologists (ACN, AC, JG, AN) using the 702 PathXL digital pathology system (http://www.pathxl.com, PathXL Ltd., UK) blinded to all other 703 clinical and pathologic variables. Immunohistochemistry for LH2 was assessed separately for 704 stromal and neoplastic epithelial components of the tumors. Stromal LH2 staining was assessed 705 with the semi-quantitative H-score which combines intensity and proportion positive 706 assessments into a continuous variable from 0-300(64). Cellular stromal components were 707 assessed (including fibroblasts, macrophages, endothelial cells, adipocytes, and other stromal 708 cell types) while areas of significant lymphocytic infiltrate were specifically excluded from the 709 percent positive estimation. Neoplastic epithelial LH2 staining intensity was scored 0-3+ based 710 on the predominant intensity pattern in the tumor -invasive tumor cells did not display 711 significant intra-tumoral heterogeneity of LH2 staining within each core. Verification of inter-712 observer reproducibility for the H-score was established in a training series of 16 cases 713 evaluated by all study pathologists to harmonize scoring. Inter-observer agreement in the 714 training set was very high, evaluating the IHC scores both as continuous variables (Pearson 715 correlation coefficients ranging from 0.912-0.9566, all p values < 0.0001), and after 716 transformation into categorical data (negative, low, and moderate/high; weighted kappa 717 coefficients ranging from 0.673-0.786). In addition, 50 cases of the study cohort were evaluated 718 blindly by two pathologists to confirm data fidelity; the Pearson correlation coefficient = 0.7507 719 (p = 5.7 E-05), considered a strong level of agreement. 720
After exclusion of cases for which LH2 was not evaluable on the TMA, H-scores for 505 patients 721
were included for statistical associations with clinicopathologic features and patient outcome. 722
Each patient was represented by two cores, and TMA core 1 and core 2 were merged into a 723 joint variable favoring the highest stromal LH2 H-score or epithelial LH2 intensity because we 724 predict that higher H-score would drive patient outcome in accordance with our gene expression 725 data demonstrating high LH2 expression correlated with poor outcome. The Pearson correlation 726 coefficient between cores = 0.647, demonstrating moderate agreement among the stromal LH2 727 H-scores for the two cores. In cases with only one TMA core providing a LH2 score, the 728 expression of this core was used. Further, the joint stromal LH2 variable was categorized into 729 tertiles based on the study population with valid LH2 annotation (N=505). The lowest tertile of 730 LH2 H-scores were defined as scores between 0 and less or equal to 120 (N=171), the 731 intermediate H-score as above 120 and equal or less than 230 (N=188), and the highest stromal 732 LH2 score as above 230 (N=146). 733
Statistical analyses for LH2 IHC analyses 734
Patient and tumor characteristics at diagnosis in relation to stromal LH2 expression were 735 categorized and presented as percentages. Continuous variables are presented as the mean 736 and min/max. The associations between LH2 expression and grade or tumor size, respectively, 737
were analyzed through linear-by-linear association. The association between LH2 expression 738 and prognosis was examined using breast cancer-specific mortality as endpoint, which was 739 defined as the incidence of breast cancer-related death. Follow-up was calculated from the date 740 of breast cancer diagnosis to the date of breast cancer-related death, date of death from 741 another cause, date of emigration or the end of follow-up as of December 31st, 2014. Main 742 analyses included the overall population; additional analyses were performed in subgroup 743 analyses stratified by estrogen receptor (ER) or axillary lymph node involvement (ALNI) status. 744
The prognostic impact of stromal LH2 expression was analyzed through Cox proportional 745 hazards analyses, which yielded hazard ratios (HR) and 95% confidence intervals (CI) for crude 746 models, and multivariate models adjusted for age at diagnosis (model 1) and tumor 747 characteristics ER (dichotomized, cut-off 10% stained nuclei), ALNI (none or any positive lymph 748 node involvement), histological grade (Nottingham grade I-III), and tumor size (dichotomized 749 using cut-off 20 mm). Kaplan-Meier curves including the LogRank test indicated LH2 status to 750 particularly impact the first 10 years after diagnosis and survival variables constructed to 751 capture these effects were used in Cox regression models investigating the effects during the 752 first post-diagnostic decade. All statistical analyses were performed in SPSS version 22.0 753 (IBM All crosslink values are normalized to total collagen content (i.e. hydroxyproline abundance) and wet tissue weight and are plotted as log2 transformed normalized peak areas from LC-MS data. Statistical analysis of crosslinks was performed using one-way ANOVA test for overall analysis and unpaired t-test was used for individual comparisons (*p < 0.05; **p < 0.01). (k,l) Heat maps of Spearman correlation coefficients indicating correlations between levels of total collagen crosslinks and collagen I content (k) and between levels of each HLCC and the top 10% of elastic modulus measurements (l) stratified by tumor subtype. Quantity of crosslinks per tissue was calculated normalizing crosslinks to total collagen content (i.e., hydroxyproline abundance) and wet tissue weight. Values were plotted as log 2 transformed normalized peak areas as quantified from LC-MS data. Statistical analyses for crosslinking data were performed using one-way ANOVA for overall comparison and unpaired t-test for individual comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). and anti-CSF1 treated (n = 5) PyMT tumor tissue stained for pan-cytokeratin (green) marking epithelial cells, F4/80 (white) marking tumor infiltrating macrophages, and DAPI marking nuclei (blue). (Second row) IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT tumor tissue stained for tyrosine 397 phosphorylated focal adhesion kinase (red) indicative of mechanosignaling and DAPI marking nuclei (blue). (Third row) Polarized light images with brightfield inset of IgG1 treated (n = 6) and anti-CSF1 treated (n = 6) PyMT tumor tissue stained with picrosirius red to visualize fibrillar collagen. (Bottom row) Lox mRNA in situ hybridization in IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT tumor tissue and DAPI marking nuclei (blue). Scale bar for all images is 100µm. (b) Quantification of the number of metastatic colonies in the lung tissues from IgG1 treated (n = 5) and anti-CSF1 treated (n = 6) mice at 11 weeks of age via PyMT IHC assessing 5 layers (5 micron section; 5 sections per layer; 50-100 microns steps). Statistical analysis was performed using unpaired t-test (*p < 0.05). (c) Quantification of fibrillar collagen by picrosirius red staining by percent area per field of view in 8 week old mice treated with anti-CSF1 blocking antibody or IgG1 control. The mean of 3-4 regions was calculated and plotted for each animal ± SEM. Statistical analysis was performed using unpaired t-test (p = 0.08). (d) Histogram showing the distribution of the top 10% of elastic modulus measurements by AFM microindentation in PyMT IgG1 treated (n =6) and anti-CSF1 treated (n = 4) tumors. Statistical analysis was performed using Mann-Whitney U test (****p < 0.0001). (e) Quantification of Lox mRNA signal by percent area of signal per field of view in 8 week old mice treated with anti-CSF1 blocking antibody (n = 5) or IgG1 control (n = 6). The mean of 5-6 regions was calculated and plotted for each animal ± SEM. Statistical analysis was performed using an unpaired t-test (*p < 0.05). (f-i) Scatter plots showing individual and mean values ± SEM of the levels of total hydroxyproline (collagen content) (f), total collagen crosslinks (g), HLCCs (h), and HLNL crosslinks (i) in 8 week old IgG1 treated and anti-CSF1 treated PyMT tumors. Quantity of crosslinks per tissue was calculated normalizing crosslinks to wet tissue weight. Values were plotted as log 2 transformed normalized peak areas as quantified from LC-MS data. Statistical analysis was performed using unpaired t-test (*p < 0.05). (j) Quantification of Tgfb1 gene expression by RT-qPCR in tumor cells, cancer-associated fibroblasts, and macrophages sorted out from PyMT tumors (n = 4). Gene expression was normalized to 18S. Statistical analysis was performed using Kruskal-Wallis one-way ANOVA for overall comparison and Mann-Whitney U test for individual comparisons (*p < 0.05, ***p < 0.001). (k) Representative images of PyMT tumor tissue from mice treated with IgG1 (n = 6) and anti-CSF1 (n = 5) stained for pan-cytokeratin (green) marking epithelial cells, SMAD2 pS465/467 (red), and DAPI marking nuclei (blue). (l) Scatter plot showing individual and mean values ± SEM of the mean nuclear intensity of pSMAD S465/467 in stromal cells of IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT mice. The mean for each animal was calculated from 4-7 regions within the tumor. Statistical analysis was performed using unpaired t-test (p = 0.06). (m-o) Scatter plot depicting the Spearman correlation of CD163 gene expression with LOX (m), PLOD2 (n), and LOXL2 (o) in human breast tumors (n = 1904). (p) Representative IHC images of serial human breast tumor sections stained for CD68 (top) and pSMAD2 S465/467 (bottom) counterstained with hematoxylin to mark nuclei. (q) Scatter plot depicting the linear regression correlation of stromal pSMAD2 IHC staining with stromal CD68 IHC staining in human breast tumors (n = 10). (r) Scatter plot depicting the linear regression of CD14 + CD11b + HLA-DR + tumor associated macrophage infiltrate with tumor elastic modulus as measured by AFM microindentation in human breast tumors (n = 15). overall survival for patients based on levels of LOX expression in epithelial cells (low n = 28, high n = 36) (a) or stromal cells (low n = 23, high n = 24) (b). The median level of expression was defined as the cutoff for low and high expression. (c-d) Kaplan-Meier plots showing overall survival for patients based on levels PLOD2 expression in epithelial cells (low n = 28, high n = 29) (c) or stromal cells (low n = 23, high n = 24) (d). The median level of expression was defined as the cutoff for low and high expression. (e) Schematic depicting the experimental timeline used to inhibit lysyl hydroxylase 2 in PyMT mice. (f) Representative polarized light images with brightfield insets of picrosirius red stained tumor tissue from PBS vehicle treated control (n = 8) and minoxidil treated (n = 7) PyMT mice. Scale bar is 100um. (g) Quantification of fibrillar collagen by picrosirius red staining by percent area per field of view. The mean was calculated and plotted for each animal ± SEM. (h) Histogram showing the distribution of the top 10% of elastic modulus measurements by AFM microindentation in PyMT control and Lox OX tumors. Statistical analysis was performed using Mann-Whitney U test (****p < 0.0001). (i) Scatter plot quantifying the area of lung sections occupied by metastases from vehicle treated (n = 9) and minoxidil treated (n = 8) mice at 13 weeks of age via H&E staining and assessing 4 layers (5 micron section; 5 sections per layer; 50-100 microns steps). Statistical analysis was performed using a two-tailed unpaired t-test (*p < 0.05). (j) Representative phase contrast images of sections from tissue microarrays (TMAs) of human breast cancers representing incident breast cancer cases collected and arrayed as 1-mm cores from each tumor. Sections were stained with Hematoxylin and Eosin (H&E; top) and lysyl hydroxylase two (LH2; bottom) via immunohistochemistry. (k) Bar graphs showing clinical correlation between lysyl hydroxylase two (LH2) score as a function of tumor grade (see Table 1 for number of patients). LH2 IHC staining was assessed with the semi-quantitative stromal specific H-score from 0 to 300. The lowest tertile of LH2 H-scores was defined as H-scores between 0 and less or equal to 120, the intermediate H-score to above 120 and equal or less than 230, and the highest stromal LH2 score as above 230. For tumor grade and LH2 H score, statistical analysis was performed using a linear-by-linear association (***P<0.0001). (l) Kaplan-Meier curves indicating cumulative breast cancer specific survival (BCSS) based on stromal LH2 H score assessed in breast cancer patients up to 10 years after diagnosis (LH2 low n = 175, intermediate n = 188, high n = 146). (m) BCSS curves by stromal LH2 H score including only axillary lymph node negative patients (LH2 low n = 116, intermediate n = 116, high n = 90). (n) BCSS curves by stromal LH2 H score including only axillary lymph node positive patients (LH2 low n = 44, intermediate n =63, high n = 54). For Kaplan-Meier curves, statistical analyses were performed by LogRank test.
